Noxopharm Limited announced two developments relating to the use of Veyondaâ to enhance the survival benefit of 177lutetium-PSMA-617 (LuPSMA) treatment in men with metastatic castrate-resistant prostate cancer. The first of these developments is important pre-clinical evidence confirming the ability of Veyonda to enhance the cancer-killing effect of LuPSMA treatment. The study was conducted by a research group led by Professor Kristofer Thurecht at The University of Queensland and had the aim of separating a combination effect (Veyonda + LuPSMA) from that of either drug alone. The study involved mice bearing tumours of human PSMA-positive prostate cancer (PC3-PIP) cells. LuPSMA was dosed on a single occasion with the equivalent of a human dose; idronoxil was dosed (rectally) twice daily for 10 days. Tumour size was recorded and mice were euthanised when tumours reached a pre-determined size, leading to a calculation of median overall survival (time when 50% of animals had died). LuPSMA alone had a clear anti-cancer effect in this model, slowing down tumour growth and extending survival substantially. However, the addition of Veyonda had an even more profound anti-cancer effect, going beyond blocking tumour growth into full regression of most of the tumours, to the extent that median overall survival could not be determined. Figure showing change in tumour volume (from starting 200-300 mm3) in mice treated with (i) suppository base alone (control group), (ii) idronoxil alone, (iii) 177Lu-PSMA-617 alone, or (iv) idronoxil + 177Lu-PSMA- 617.